Showing results (81-90 of 136) with videos related to
Sort By:
Pageof 14
BJUI Compass|April 7, 2023
PemBla: A Phase 1 study of intravesical pembrolizumab in recurrent non-muscle-invasive bladder cancerVictoria K Woodcock, Ji-Li Chen, Karin Purshouse, et al.Cancer Chemotherapy and Pharmacology|May 23, 2023
Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanomaDrew W Rasco, Theresa Medina, Pippa Corrie, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1E Ruth Plummer, Mark R Middleton, Christopher Jones, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2007
Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanomaMalcolm Ranson, Peter Hersey, Damien Thompson, et al.Cancers|April 30, 2021
Activated Regulatory T-Cells, Dysfunctional and Senescent T-Cells Hinder the Immunity in Pancreatic CancerShivan Sivakumar, Enas Abu-Shah, David J Ahern, et al.JAMA Oncology|December 14, 2018
Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical TrialDejan Juric, Filip Janku, Jordi Rodón, et al.Cancer|October 18, 2018
A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancerToby A Eyre, Graham P Collins, Avinash Gupta, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 21, 2022
VCAM-1-targeted MRI Improves Detection of the Tumor-brain InterfaceVinton W T Cheng, Nicholas de Pennington, Rasheed Zakaria, et al.Journal of the National Cancer Institute|March 29, 2013
P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanomaChristy C Ong, Adrian M Jubb, Diana Jakubiak, et al.Cancers|January 13, 2019
The Circulating Transcriptome as a Source of Biomarkers for MelanomaCarla Solé, Daniela Tramonti, Maike Schramm, et al.Pageof 14